Company news
Percheron Therapeutics Limited news in 2019
Percheron Therapeutics Limited's news releases, calls and decks from 2019, newest first.
Positive results reaffirm plans to advance ATL1102 to P2b
December 16, 2019
Suspension from Official Quotation
December 15, 2019
AGM Presentation 2019
December 11, 2019
Dosing completed in ATL1102 Phase II DMD trial
November 19, 2019
Appendix 4C - quarterly
October 24, 2019
Response to ASX Price Query
October 7, 2019
Positive preliminary results from ATL1102 DMD Phase II trial
September 18, 2019
ATL1102 for DMD European regulatory interactions
September 2, 2019
Acromegaly Early Access Program Status Update
August 26, 2019
Phase II DMD clinical trial on track for dosing completion
July 24, 2019
Phase II clinical trial in DMD Fully Enrolled
May 23, 2019
Phase II clinical trial in DMD Update
April 3, 2019
Placement to Accelerate Development of ATL1102 in DMD
March 12, 2019
Pause in trading
March 10, 2019
Decks in 2019
- Shareholder Meeting (December 2019)
Shareholder meeting · 26 slides · Dec 11, 2019